NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

News and Articles
Sep 2 2009

PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) (“PharmaGap” or “the Company”) today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company’s lead drug GAP-107B8.

Results from the initial NCI single dose study released on August 24 showed greater than 50% effect of GAP-107B8 in reduction of cancer cell growth in 26 of the 57 human cancer cell lines tested. Compelling results were found in all 9 cancer types tested, with very positive results in melanoma, breast, central nervous system, and prostate cancers.

The initial test used a single low dose (10(micro)M) to evaluate the effect of GAP-107B8 against the 57 cancer cell lines in the test. In specific melanoma, breast, central nervous system, and prostate cancer cell lines, growth inhibition of 100% was observed (the announcement of results can be found on the Company’s website www.pharmagap.com).

Following these compelling results in the initial one-dose testing protocol, GAP-107B8 was selected for testing by the NCI in the same NCI-60 tumour cell panel using five dose concentrations. This range of doses is intended to further examine the drug’s effectiveness in human cancer tumour cells, to allow further characterization of the drug’s activity against various cancer types, and to provide insight into its method of action.

The NCI-60 protocol tests a wide variety of cancers, including breast, colorectal, lung, ovarian, kidney, prostate, leukemia and various central nervous system cancers and melanomas.

Source:

PHARMAGAP INC.

Source: www.news-medical.net

Rate article
Add a comment